Bosutinib for the treatment of Philadelphia chromosome-positive leukemias

Bibliography

• HJLee, JEThompson, ESWang, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011;117(8):1583-94
   PubMed Web of Science ®Google Scholar
• LCChan, KKKarhi, SIRayter, et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987;325(6105):635-7
   PubMed Web of Science ®Google Scholar
• RKurzrock, MShtalrid, PRomero, et al. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature 1987;325(6105):631-5
   Google Scholar
• CAWestbrook, CMRubin, JJCarrino, et al. Long-range mapping of the Philadelphia chromosome by pulsed-field gel electrophoresis. Blood 1988;71(3):697-702
   Google Scholar
• DAThomas, SFaderl, JCortes, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103(12):4396-407
   PubMed Web of Science ®Google Scholar
• DJones, DThomas, CCYin, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008;113(5):985-94
   PubMedGoogle Scholar
• WKHofmann, LCJones, NALemp, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002;99(5):1860-2
   PubMed Web of Science ®Google Scholar
• SSoverini, CDe Benedittis, CPapayannidis, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 2014;120(7):1002-9
   PubMed Web of Science ®Google Scholar
• FXMahon, FBelloc, VLagarde, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101(6):2368-73
   PubMed Web of Science ®Google Scholar
• LWang, AGiannoudis, SLane, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83(2):258-64
   PubMed Web of Science ®Google Scholar
• SLi. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008;49(1):19-26
   PubMed Web of Science ®Google Scholar
• FFei, SStoddart, MMuschen, et al. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia 2010;24(4):813-20
   Google Scholar
• LLRemsing Rix, URix, JColinge, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23(3):477-85
   PubMed Web of Science ®Google Scholar
• URix, JColinge, KBlatt, et al. A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. PLoS One 2013;8(10):e77155
   PubMed Web of Science ®Google Scholar
• GKAmsberg, SKoschmieder. Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. Onco Targets Ther 2013;6:99-106
   PubMed Web of Science ®Google Scholar
• MPuttini, AMColuccia, FBoschelli, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66(23):11314-22
   PubMed Web of Science ®Google Scholar
• JMGolas, KArndt, CEtienne, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63(2):375-81
   PubMed Web of Science ®Google Scholar
• MMancini, GBrusa, EZuffa, et al. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. Leuk Res 2007;31(7):979-87
   PubMed Web of Science ®Google Scholar
• YHu, YLiu, SPelletier, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36(5):453-61
   Google Scholar
• RAbbas, BAHug, CLeister, et al. A Phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol 2012;69(1):221-7
   PubMed Web of Science ®Google Scholar
• RAbbas, CLeister, DSonnichsen. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig 2013;33(8):589-95
   Web of Science ®Google Scholar
• RAbbas-Borhan, IChaudhary, BAHug, et al. Mass balance, metabolic disposition, metabolite characterization, and pharmacokinetics of oral 14C-labeled bosutinib in healthy subjects. The 9th triennial meeting of the international society for the study of xenobiotics; 4–8 September 2010; Istanbul, Turkey
   Google Scholar
• Pfizer. Bosutinib prescribing information 2014
   Google Scholar
• CHegedus, COzvegy-Laczka, AApati, et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009;158(4):1153-64
   PubMed Web of Science ®Google Scholar
• PPerini. Role of the drug transporters in the multidrug resistance affecting bosutinib treatment. BICOCCA, Milan, Italy; 2011
   Google Scholar
• JECortes, HMKantarjian, THBrummendorf, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118(17):4567-76
   PubMed Web of Science ®Google Scholar
• CGambacorti-Passerini, THBrummendorf, DWKim, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol 2014;89(7):732-42
   PubMed Web of Science ®Google Scholar
• THBrummendorf, JECortes, CAde Souza, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 2015;168(1):69-81
   PubMed Web of Science ®Google Scholar
• SRedaelli, LMologni, RRostagno, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 2012;87(11):E125-8
   PubMed Web of Science ®Google Scholar
• HJKhoury, JECortes, HMKantarjian, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119(15):3403-12
   PubMed Web of Science ®Google Scholar
• CGambacorti-Passerini, JCortes, HKantarjian, et al. Bosutinib (SKI-606) shows high tolerability and clinical activity in patients with philadelphia chromosome positive leukemias. Haematologica 2008;93(Sl):160-1
   Google Scholar
• HMKantarjian, JECortes, DWKim, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014;123(9):1309-18
   PubMed Web of Science ®Google Scholar
• CGambacorti-Passerini, JECortes, JHLipton, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014;89(10):947-53
   PubMed Web of Science ®Google Scholar
• PLe Courte, DRea, EAbruzzese, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011;103(17):1347-8
   Google Scholar
• KJAichberger, SHerndlhofer, GHSchernthaner, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86(7):533-9
   PubMed Web of Science ®Google Scholar
• DMontani, EBergor, SGünther, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125(17):2128-37
   PubMed Web of Science ®Google Scholar
• EJabbour, HMKantarjian, GSaglio, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123(4):494-500
   PubMed Web of Science ®Google Scholar
• MTKrauth, SHerndlhofer, MTSchmook, et al. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 or 500 mg daily. Haematologica 2011;96(1):163-6
   Google Scholar
• HKonig, TLHolyoake, RBhatia. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008;111(4):2329-38
   PubMed Web of Science ®Google Scholar
• KDe Keersmaecker, MPorcu, LCox, et al. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. Haematologica 2014;99(1):85-93
   Google Scholar
• CGraux, JCools, CMelotte, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004;36(10):1084-9
   Google Scholar
• GDMiller, BJBruno, CSLim. Resistant mutations in CML and Ph (+)ALL - role of ponatinib. Biologics 2014;8:243-54
   PubMedGoogle Scholar
• CCAnderson. Phase I/II study of bosutinib in combination with inotuzumab ozogamicin in CD22-positive Philadelphia-Chromosome (PC) positive acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). Available from: https://clinicaltrials.gov/ct2/show/NCT02311998 [Last accessed 25 March 2015]
   Google Scholar